Message from Leinco Technologies: Antibody Pricing Stability Amid Market Shifts
St. Louis, MO, 17 June, 2025 - Leinco Technologies remains committed to supporting the global scientific community by ensuring consistent access to high-quality recombinant antibodies and reagents—without unexpected price increases. As tariffs and international trade [...]
Leinco Technologies Launches Groundbreaking ADAPT-3D™ Tissue Clearing Kit to Accelerate 3D Fluorescence Imaging
St. Louis, MO, 25 April, 2025 - Leinco Technologies, a leading innovator in life science research and diagnostic solutions, is proud to announce the launch of its ADAPT-3D Tissue Clearing Kit. This new offering is [...]
Leinco Technologies Awarded $1M Grant to Develop Rapid Test for Intestinal Immunity to Polio
St. Louis, MO, February 6, 2025 - Leinco Technologies, a leader in antibody and protein development, is thrilled to announce that it has been awarded a $1M grant from the Gates Foundation. The grant aims [...]
Leinco Technologies Welcomes Dr. Stephen T. Haley as Vice President of Business Development
St. Louis, MO, December 3, 2024 - Leinco Technologies is proud to announce the appointment of Dr. Stephen T. Haley as our new Vice President of Business Development. Dr. Haley brings over 20 years of [...]
Leinco Technologies Inc. Acquires QED Biosciences, Leading Provider of Antibodies, Related Reagents, and Development Services
The strategic acquisition will enable Leinco to expand its portfolio of antibody capabilities used globally for research and diagnostics. St. Louis, MO, September 3, 2024 - Leinco Technologies (“Leinco”), a trusted source of high-quality [...]
Launch of chimeric anti-mouse PD1 and PD-L1 recombinant antibodies
Leinco Technologies Highlights Launch of the new mAbMods™ chimeric anti-mouse PD1 and PD-L1 recombinant antibodies for use in in vivo functional studies ST. LOUIS, April 17, 2023 –Leinco Technologies (“Leinco”) ( St. Louis, MO), a [...]
